SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " bio " 2,879 found 🔀 AI-powered Shuffle
Pace appoints Andy Fenny as president to drive life science growth
Pace, a science and technology company, has appointed Andrew (Andy) Fenny as president of Pace Life Sciences, the organization’s life sciences division, to lead the business into its next phase of strategic growth with a focus on expanding support and capacity for pharmaceutical and biotech clients across the development cycle.
Beer, wine or liquor? Massive study reveals which was linked to lower death risk
Heavy alcohol use raised death risk by 24%, but wine at low levels was linked to lower mortality than beer or spirits in a UK Biobank study.
Why This Shark Glows in the Dark—and What Scientists Just Discovered About It - Futura-Sciences
The Glow of the Kitefin Shark The kitefin shark (Dalatias licha) is a master of the twilight zone, cruising the deep-sea gloom like a spectral submarine. Like many marine creatures, it produces its own blue-green light. Until recently, scientists believed this bioluminescence mainly helped the shark perform what’s called “counter-illumination”—by...
AI needs science’s search history
“Actually, that’s where the gold is,” said Alasdair Russell, my graduate school friend who leads a pre-clinical genome editing group at Cambridge. He was talking about the winding road of science that is omitted from published papers. “When you’re discussing how to do the experiment, and why this way is better than another way, and what does the data really mean? I know what it shows, but what does it mean?” At RAAIS 2026, he described how his group has begun logging the twisting path of discovery as it happens, recording the verbal and written exchanges that normally disappear. Ideas become nodes in a living graph: they branch when a meeting produces two plausible experiments, merge when separate lines of evidence converge, and go dark when someone quietly stops pursuing them. In his implementation, one agent scores novelty, while another tries to learn “how scientists think and how they navigate through a complex world of data,” so that high-potential nodes can trigger deeper investigation. As frontier AI labs deploy agents toward scientific discovery, giving AI authentic scientific taste remains a trillion-dollar dilemma. The bottleneck is that the record we have kept for centuries of science might be insufficient to get us there. The experiments that never make the paper Peter Medawar, 1960 Nobel laureate and “father of transplantation,” asked in 1963 whether the scientific paper was a fraud, and answered yes: the form of the paper misrepresents the thinking that produced it. Sixty years on, the diagnosis is unchanged. A paper presents a clean progression from hypothesis to result to conclusion. Lost along the way are the unconventional theories, the abandoned or unaffordable methods, and the underwhelming and inconclusive data. It reads like a browser history with every dead end deleted: the ten open tabs, the four rephrased queries, the wrong turn down a subforum. All scrubbed, leaving one clean path from question to answer as the canonical path. What has changed since then is that the discarded material is now worth something. No high-impact journal wants these artifacts, but raw trial and error is the most likely source of the training data required to develop scientific intuition, or what researchers call taste. Earlier attempts to capture the discards were motivated by scientific integrity. The Journal of Negative Results in Biomedicine launched in 2002 to publish rigorous studies that disputed established models or exposed ineffective treatments. Its archive preserved negative conclusions after they had become papers, rather than the live alternatives and arguments that produced them. BioMed Central closed it in 2017, saying the mission had been served now that other journals publish null results. A less generous reading is that in fifteen years it published around 200 papers because almost nobody wants to read a negative result, let alone write one up when it will not count toward academic tenure. AI models are different. Even an uninteresting negative result can be useful, provided it is labeled. Earlier this year, Anthropic put a version of this to the test. The company pulled 129 decision points from real Claude Code sessions between January and March 2026, showed models the work up to a human detour, and asked what should happen next. Claude Mythos Preview beat the human choice 64% of the time, while Opus 4.5 managed 51%. The comparison was tilted toward the models because Anthropic deliberately chose moments where the human decision had room for improvement. On 127 further scenarios where the human action was already strong, the models improved on it only about 20% of the time. The study was possible because Anthropic’s researchers work inside a tool that logs by default. The reasoning, detours and outcome are produced in the same working environment. Biology has no equivalent. Its reasoning happens in hallways, at benches, in Slack threads and on whiteboards, while the outcome arrives weeks later somewhere else. The record has to emerge from the work itself. Ask scientists to reconstruct it afterwards and we’ll create another polished account. Subscribe A log is not a label Before any of this becomes training data, a negative result has to say what failed. The first paper published in the Journal of Negative Results in Biomedicine examined 234 negative studies across five leading medical journals. Only 30% discussed statistical power, and half clearly defined a primary outcome. Tell a model an experiment failed, without telling it whether the assay was underpowered, a reagent had degraded, or the hypothesis was simply wrong, and it will learn noise with confidence. Decision histories have a second missing label too. When a lab considers five experiments and runs one, only the chosen branch returns an outcome. The other four are experimental counterfactuals. Researchers call this the selective labels problem: the data reveal results only for the actions someone chose to take. Such a record can teach a model to imitate a lab’s taste, but it cannot establish that the taste was good. It also smuggles local constraints into general lessons. A lab that never ran cryo-EM because it did not own a microscope teaches a model that cryo-EM is rarely the right call. Alasdair’s nodes preserve the candidate set, which is the necessary first step. To be useful, each decision record needs six fields: The evidence available at that moment, and nothing that arrived later. The candidates considered, including the ones dismissed in a sentence. For each candidate: the expected result, the confidence attached to it, and the cost in time and money. The route chosen, and the reason. What happened next. How the evidence changed the scientist’s view. These must be timestamped before the outcome, because hindsight turns uncertainty into inevitability. Disagreement also has to survive. Averaging three scientists into one clean rationale reproduces exactly the information loss we are trying to fix. But there is an obvious failure mode here. Once decisions are logged and scored, people log for the record post-facto. Anyone who has watched an electronic lab notebook fill up with retrospective tidying knows how quickly a research tool becomes a compliance exercise. A record that costs a scientist ten minutes of honest reflection per decision is worth far more than one that costs an hour of performance. A publication initiative called Registered Reports offers a useful starting point. Here, researchers submit their rationale, methods and analysis plan for peer review before the data exist, and the journal commits in principle to publish if they follow the approved plan. Nature has now expanded the format across every field it covers. This approach to paper writing timestamps intent before the outcome, but it freezes one plan. A useful search history must also preserve how the plan changed, which alternatives were rejected, when, and on what evidence. Subscribe Run the runner-up Autonomous labs show what happens when decisions and outcomes are connected in a loop. Liverpool’s mobile robotic chemist ran 688 experiments over eight days in a ten-variable formulation space. A batched Bayesian search used each result to choose the next experiments and found photocatalyst mixtures six times more active than the starting formulations. Every completed experiment changed what the system did next. The robot optimized within a goal and search space that humans had already chosen. It did not decide which scientific question mattered. So what this work demonstrates is narrower, but still useful: a search history pays off when the options return standardized outcomes quickly. Open-ended biology is harder because branches can take weeks and the discarded alternatives may never be run. Some exploration therefore has to be bought. Where two branches are plausible and the stakes justify the cost, a lab should sometimes run the runner-up. Otherwise the record captures what today’s scientists usually chose and stays silent on what they systematically overlooked. A funder could ring-fence a small fraction of a grant for the branch not taken, provided that the decision record and the outcome are both deposited. That costs money, but so does having every lab rediscover the same abandoned path. Test whether taste transfers When it comes time to evaluate if our new AI system exhibits taste, the comparison should run across laboratories and fields. At selected decision points in a live research campaign, we should freeze the six fields: the evidence, the candidates, expected results, confidence, costs and the choice made. Experts then rank the options before the outcomes are known, and those outcomes are checked independently later. We could give models one of two diets - papers alone, or papers plus decision histories - and ask them to rank the next experiment on unfamiliar projects. Then, we score information gained per dollar and week, calibration, and how quickly weak branches are abandoned. If histories improve choices only inside the lab that produced them, they amount to useful organizational memory. If they improve choices on unfamiliar problems elsewhere, Alasdair’s group will have captured something science has never managed to write down: a transferable record of taste. Until that happens, a scientific search history is a promising record, not yet a training set.
Rubio and Bessent stayed on decoy flight as Trump switched planes, official says
Trump was secretly moved to a smaller military jet due to a threat
Scientists develop innovative hybrid material for hydrogen peroxide production
Recently published research from a team led by scientists at Argonne National Laboratory demonstrates how a hybrid of biological components and technology can be used to efficiently produce hydrogen peroxide and other chemicals.
State Dept axes Biden-era DEI scheme pushing woke politics across the globe and more top headlines
Get all the stories you need-to-know from the most powerful name in news delivered first thing every morning to your inbox.
Seven Virginia Tech faculty elected to 2026 Virginia Academy of Science, Engineering, and Medicine
The new members represent the university's research breadth in wireless communications, cybersecurity, cancer biology, medical education, AI, drug delivery, and comparative oncology.
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
/PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative...
INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis...
Albion reject Derby bid for midfielder Mowatt
West Bromwich Albion reject a bid for midfielder Alex Mowatt from fellow Championship club Derby County, reports BBC Radio WM.
Astorg Acquires Thermo Fisher Microbiology Business, Forms Independent Company
Astorg has completed its acquisition of Thermo Fisher’s microbiology business, which will operate independently under CEO Dirk Bontridder.
USPTO Expands Category A Patent Bar Admission Criteria to Include Biomedical Science Degree
The USPTO published a Federal Register Notice Tuesday announcing administrative updates to the General Requirements Bulletin (GRB).
Joint Statement by Secretary of Health and Human Services Robert F. Kennedy, Jr. and Secretary of State Marco Rubio: United States to Serve as Secretariat of the Geneva Consensus Declaration
Joint statement from HHS Secretary Kennedy and Secretary of State Rubio on the Geneva Consensus Declaration.
‘The Traitors: New Blood’ first ever all-civilian cast revealed (exclusive)
‘The Traitors: New Blood’ first ever all-civilian cast is revealed with photos, bios, and interviews with the 22 new Faithfuls and Traitors.
Screwworm neutralizer: insect sterilization | Investors Lab
The fight against screwworm has moved beyond traditional government programs into an arena ripe for biotech intervention:
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up...
Huge Helldivers 2 Patch Adds New Illuminate Enemies, a New Biome 'Full of Fresh Horrors,' a Level Cap Increase and Much More
Helldivers 2 developer Arrowhead has released a major update for the game, adding new Illuminate enemies, a new biome, and raising the level cap. Check out the 7.0.0 patch notes.
Advancing the science of dietary nitrate with integrated vascular assessment
Standardised beetroot-derived dietary nitrate supports endothelial function, arterial compliance, central haemodynamics and nitric oxide bioavailability, thereby promoting systems-based research in vascular nutrition
Scientists find evidence for two origins of life on Earth
Scientists probing life’s deepest origins have uncovered evidence that the first free-living cells may have emerged not once, but twice. The findings suggest a striking possibility: life may share one ancient genetic code, yet have undergone two separate transitions into free-living existence.
Intertidal: Bioluminescence is science, but still feels like magic
In the long days of summer, there is so much light that darkness holds a special magic. One of my favorite things to do on summer evenings is to be out in the darkness. And some of the most magical things about summer's darkness are the unexpected lights.
Reimagining Science Education in West Africa with Sankofa Lab
David Tettey Tawiah ’27 is taking what he learned at Colby and the MDI Bio Lab to inspire a new generation of West African scientists
Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
Multi-year collaboration combines ongoing glucose insights from Abbott's Lingo biowearable with Google Health's technology to create a more comprehensive view of personal health Partnership...
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
/PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the...
Lallemand Bio-Ingredients to spotlight science-driven ingredients at Vitafoods Asia 2026
Lallemand Bio-Ingredients, Health Ingredients, a global leader in fermented functional ingredients for human health and nutrition, will showcase its latest science-backed ingredients at Vitafoods Asia 2026, taking place September 2-4, 2026, in Bangkok, Thailand
Radiologists criticize noted neuroscientist podcaster’s claims supporting whole-body MRI
Andrew D. Huberman, PhD, a professor of neurobiology and ophthalmology at Stanford Medicine, voiced support for these scans in a recent social media post.
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed,...
Scientists Release Biggest 2D Map of the Universe
Key Takeaways The DESI Legacy Imaging Surveys combined more than 263,000 telescope exposures to make the largest 2D map of the universe in visible and near-infrared light. Astronomers can pair the Legacy Surveys map with their own observations to explore our universe and search for rare phenomena. The 2D map serves as the foundation for the Dark Energy Spectroscopic Instrument survey to measure the universe in 3D and investigate dark energy. Hold on to your telescopes: the DESI Legacy Imaging Surveys team has released the largest-ever 2D color map of the universe. The 5.6-trillion-pixel map contains nearly 4 billion celestial objects, primarily stars and galaxies. The data is available for all to use and publicly viewable through the Legacy Survey Sky Viewer. Astronomers and citizen scientists can explore the map or combine it with their own observations to better understand our universe. Researchers can search for rare phenomena like gravitational lenses, observe fleeting events like supernovae, and investigate two of physics’ biggest mysteries: dark matter, the invisible substance that accounts for most of the mass in our universe, and dark energy, the force driving our universe’s accelerating expansion. The new map builds on earlier versions from the DESI Legacy Imaging Surveys that have already proved invaluable. To date, more than 1,800 science papers that reference the Legacy Surveys data have been published. “It’s part of the fabric of astronomy research now,” said David Schlegel, a co-lead of the Legacy Surveys and scientist at the Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab). “When you’re working with astronomical objects today, you often start by pulling up the Legacy Imaging Viewer to see what you’re looking at.” Covering roughly 75% of the sky in visible and near-infrared light, the updated map provides a deep view of the extragalactic universe not blocked by the dust and stars of our own Milky Way. Researchers expect it will remain the most comprehensive 2D map of our universe for years to come. More than 160 scientists contributed to data collection for the project, and a team of 20 produced the final dataset released today. It was built by combining 263,407 telescope exposures from three ground-based sky surveys: the Dark Energy Camera Legacy Survey (DECaLS) at NSF Cerro Tololo Inter-American Observatory, the Mayall z-band Legacy Survey (MzLS) at NSF Kitt Peak National Observatory, and the Beijing-Arizona Sky Survey (BASS) at the University of Arizona’s Steward Observatory. That was supplemented by years of data from NASA’s Wide-field Infrared Survey Explorer (WISE) satellite mission and additional public data. “For our team, these data are fundamental to our investigation of the expansion history of the universe and the formation of our galaxy,” said Arjun Dey, co-lead of the Legacy Surveys and an astronomer at NSF NOIRLab. “But the skies belong to everyone, and this survey gives everyone the chance to explore the sky and marvel at its wonders.” Here be galaxies The DESI Legacy Imaging Surveys were originally conducted to prepare for the Dark Energy Spectroscopic Instrument (DESI) survey. The Legacy Surveys’ 2D map is essentially a deep photograph of the sky; it records where galaxies and stars appear and how bright they appear. This crucial step enables DESI to select objects and measure their light in different wavelengths to determine their distances, building the largest high-resolution 3D map ever made. Scientists study the way galaxies have clustered at different ages of the universe to track dark energy over time. In April 2026, DESI completed its original five-year survey ahead of schedule and with vastly more objects than expected. The early results have shown surprising hints that dark energy’s impact may be weakening over time — a paradigm shift that could potentially shape the predicted fate of our universe. DESI expects to publish improved results using their first five years of data in 2027 and is continuing observations into 2028. DESI was so efficient at observing galaxies, the Legacy Surveys map needed to expand. Early on, “it became clear we might run out of galaxies to look at and run out of sky, and we better start doing something about that,” said Schlegel, who also works on DESI. The new Legacy Surveys map has been used to select DESI targets since June 2026 and will guide the telescope’s operations over the coming years. Computing the cosmos Merging hundreds of thousands of images taken on 2,285 nights, each with unique atmospheric and telescope conditions, was a massive computational effort. It took about a year to develop the computer code and eight weeks to process all the images at the Perlmutter supercomputer at the National Energy Research Scientific Computing Center (NERSC) at Berkeley Lab. Beyond supporting DESI, the Legacy Surveys will be a foundational reference for the next generation of telescopes. As new observatories like the NSF-DOE Vera C. Rubin Observatory (jointly funded by NSF and DOE’s Office of Science) and NASA’s Nancy Grace Roman Space Telescope come online, researchers can compare their observations with one of the deepest and most comprehensive views of the sky ever assembled. The Legacy Surveys data will also help scientists train artificial intelligence tools to analyze petabytes of astronomical data and accelerate new discoveries. It will be among the datasets used in an astrophysics pilot project within the American Science Cloud, part of the DOE’s Genesis Mission. The DESI Legacy Imaging Surveys are supported by the U.S. Department of Energy’s Office of High Energy Physics; the National Energy Research Scientific Computing Center, a DOE Office of Science user facility; the U.S. National Science Foundation, Division of Astronomical Sciences; and the partner institutions. DESI is supported by the DOE Office of Science and NERSC. Additional support for DESI is provided by the NSF; the Science and Technology Facilities Council of the United Kingdom; the Gordon and Betty Moore Foundation; the Heising-Simons Foundation; the French Alternative Energies and Atomic Energy Commission (CEA); the Secretariat of Science, Humanities, Technology and Innovation (SECIHTI) of Mexico; the Ministry of Science and Innovation of Spain; and by the DESI member institutions. ### Lawrence Berkeley National Laboratory (Berkeley Lab) is committed to groundbreaking research focused on discovery science and solutions for abundant and reliable energy supplies. The lab’s expertise spans materials, chemistry, physics, biology, earth and environmental science, mathematics, and computing. Researchers from around the world rely on the lab’s world-class scientific facilities for their own pioneering research. Founded in 1931 on the belief that the biggest problems are best addressed by teams, Berkeley Lab and its scientists have been recognized with 17 Nobel Prizes. Berkeley Lab is a multiprogram national laboratory managed by the University of California for the U.S. Department of Energy’s Office of Science. DOE’s Office of Science is the single largest supporter of basic research in the physical sciences in the United States, and is working to address some of the most pressing challenges of our time. For more information, please visit energy.gov/science.
Thousands of Endangered Species Condoms Distributed to Health Clinics, Mutual Aid Groups After Federal Funding Cuts
TUCSON, Ariz.— The Center for Biological Diversity has distributed more than 20,000 free Endangered Species Condoms so far this year to health clinics, mutual aid groups and social service organizations in the wake of federal funding cuts, including recent cuts to the Teen Pregnancy Prevention Program.
VOTE: Do you think biological males should be allowed to play women’s sports?
KBOI-TV CBS 2 covers news, sports, traffic, and weather in the Treasure Valley and Boise, Idaho and nearby communities, including Meridian, Nampa, Garden City, Caldwell, Kuna, Middleton, Eagle, Mountain Home, Star, Melba, Payette, Weiser, Horseshoe Bend, Idaho City, Marsing, Homedale, Parma, New Plymouth, Murphy, Fruitland, Emmett, Wilder, Notus, McCall, Cascade, Donnelly, Council, and Vale, Oregon, and Nyssa, Oregon, Ontario, Oregon.
Hands-On Learning, Mentorship Launch Science Grad’s Next Chapter
A chemistry grad’s next stop is Stanford University, but the path that led him there was shaped in the classrooms, labs and research groups at the University of Guelph. Peter Kim’s love for science…
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
AbCellera has reported phase 2 results “beyond even the most aggressive upside scenario” that its CEO dared to consider, boosting the biotech’s chances of challenging Astellas and Bayer for a women’s health market. The phase 2 clinical trial compared ABCL635, an antibody targeting NK3R, to placebo in patients with hot flashes caused by menopause. Investigators enrolled 92 postmenopausal women experiencing a mean of about 10 moderate or severe hot flashes per day. By Week 4, the number of moderate or severe hot flashes had fallen by a mean of 8.8 on ABCL635 and by 3.5 on placebo. That statistically significant, placebo-adjusted reduction of 5.3 hit the trial’s primary endpoint. The level of efficacy also cleared the bar set by existing drugs. While cross-trial comparisons can be misleading, AbCellera CEO Carl Hansen, Ph.D., had seen enough to start hyping the program. “We now view ABCL635 as a potential best-in-class non-hormonal therapy with strong differentiation against approved NK3R competitors across all important dimensions, including efficacy, safety, dosing and convenience,” Hansen said on a Monday morning conference call with investors to discuss the data. “We believe ABCL635 is now a highly de-risked program.” Last week, Hansen used AbCellera’s earnings call to set expectations for readout, with the CEO defining success as a clean safety profile and efficacy comparable to the two approved small molecules. The data vaulted over that bar. Astellas linked (PDF) one of the small molecules, Veozah, to placebo-adjusted reductions in hot flash frequency of 2.1 and 2.6 at Week 4 of its two phase 3 trials. Bayer reported (PDF) placebo-adjusted reductions of 3.04 and 3.29 at Week 4 of pivotal studies for its small molecule, Lynkuet. At 5.3, the placebo-adjusted reduction in AbCellera’s trial comfortably cleared the standard set by the incumbents. Veozah and Lynkuet came to market based on evidence of their ability to reduce the frequency and severity of hot flashes. AbCellera’s phase 2 study covered both endpoints, with the Canadian biotech reporting a mean reduction in severity of 1.4 points at Week 4 on ABCL635, compared to 0.3 points for placebo. Again, the placebo-adjusted result compares favorably to data on Veozah and Lynkuet. Analysts shared Hansen’s enthusiasm for the data. The phase 2 results “firmly validate ABCL635 as a potentially best-in-class treatment,” BMO Capital Markets analysts said in a note to investors Monday. ABCL635’s apparent efficacy edge “is likely attributable to the higher dosing/target engagement the asset is able to reach vs. the oral agents due to its wider therapeutic index,” the analysts added. The analysts, who model $2.3 billion in unadjusted peak sales for ABCL635, flagged the safety profile as another positive of the phase 2 readout. While Veozah carries a boxed warning for liver damage, nobody on ABCL635 in the phase 2 trial had elevated liver enzymes or bilirubin values. If replicated in phase 3, the lack of a liver signal could allow approval without the monitoring requirements imposed on Veozah. Investors appeared equally enthused, sending AbCellera's stock up 32% to $9.21 in premarket trading Monday from a Friday closing price of $6.93. Next, AbCellera will collect the Week 12 data and talk to its advisors about further development. The results open up “a wide variety of possibilities of how we might take this forward into phase 3 studies to truly maximize the value of the asset and make sure that ABCL635 is able to demonstrate its differentiation potential,” Sarah Noonberg, M.D., Ph.D., AbCellera’s chief medical officer, told investors.
Ott receives leadership award from Society for the Study of Reproduction
Troy Ott, Peter and Ann Tombros Dean of Penn State’s College of Agricultural Sciences, has received the Distinguished Leadership and Service Award from the Society for the Study of Reproduction, one of the organization’s highest honors recognizing exceptional leadership and selfless service in advancing the science of reproductive biology.
NSF grant supports Marley Dewey’s work to restore coral reefs
UC Santa Barbara assistant professor of bioengineering Marley Dewey is bringing in a wider community as she studies how to repair coral, as part of a $750,000 CAREER award from the National Science Foundation.
Michael Jackson’s nephew shares never-before-seen photos from the set of ‘Michael’ (exclusive)
The hit biopic will be available to stream on Starz on Monday.
Review | Jeremy Jordan keeps ‘Just in Time’ swinging after Jonathan Groff
"Just in Time" is a bio-musical that follows Bobby Darin, the singer who rose to fame with “Splish Splash.”
National Grid's BioBus brings science lab to Albany's Lincoln Park
WRGB CBS 6 provides local news, weather forecasts, traffic updates, notices of events and items of interest in the community, sports and entertainment programming for Albany, New York and nearby towns and communities in the Capital City area, including Cohoes, Watervliet, Colonie, Bethlehem, Guilderland, New Scotland, Coeymans, Green Island, Knox, Berne, Westerlo, Rensselaerville, Colonie, Menands, Green Island, Ravena, Altamont, Voorheesville.
These 'five pillars' for living healthier longer are easy and affordable
Longevity has become a bit of a buzz word, and has become increasingly aligned with the tech industry. But while it remains unclear whether the billions of US dollars being invested in life-extending bioscience is something any of us can access, a timely report from Harvard Medical School reminds us what we can do on our own – and it's backed by a huge body of evidence.
Translating Science into Practical Management Solutions
Biology in the barn can translate science into practical management solutions
AI just created a virus not found in nature and scientists are worried
The technique could lead to new treatments for antibiotic-resistant bugs, but some scientists say the technology could be misused
$500K National Science Foundation Grant funds interdisciplinary mathematical biology research at Elon
The National Science Foundation (NSF) has awarded Associate Professor of Mathematics Hwayeon Ryu and Assistant Professor of Biology Efra Rivera-Serrano a three-year, $500,138 grant to study viral...
Uberaba Geopark: A time capsule from the Late Cretaceous period nestled in Brazil's tropical savanna
Uberaba Geopark, also known as the "Land of the Giants," is a region in Brazil's Cerrado biome that preserved thousands of prehistoric fossils.
Scientists Are Starting To Understand The 'Largest Biomechanical Event on Earth': Whales Hunting For Food on a Single Breath
If your heart slowed that much, you'd probably pass out.
Scientists Trained An AI Model In DNA—And It Invented 16 New Viruses
Scientists are worried about how smart DNA-trained artificial intelligence models could get—and that they could become a weapon in biological warfare.
Supporters of a bipartisan bill say America’s biotechnology future depends on measurement science
I think the success will be that there are uniform standards that could be used by AI, by international scientists," said Congresswoman April McClain Delaney.
Meister awarded "Top 10 Science Breakthrough" for 2026
Assistant Professor Konrad Meister from the Department of Chemistry and Biochemistry was named in the...
Safety fears as scientists make first viruses designed by AI
Researchers say breakthrough offers hope for new medicines but also raises urgent biosecurity questions
Republican senators file amendment to stop college sports bill from overriding state women's sports laws
Republican senators filed an amendment to ensure the Protect College Sports Act cannot preempt state laws banning biological males from women's sports.
Morgridge hosts annual science camp for rural high school students
The Morgridge Institute’s Rural Summer Science Camp allows Wisconsin high school students to experiment in the University of Wisconsin-Madison’s world-class bioscience labs.
Trump told donors 'we need to elect JD,' source confirms, as he weighs Vance or Rubio in 2028
President Donald Trump told Republican donors "we need to elect JD" in a private Oval Office meeting, a source confirmed to Fox News Digital.
Science Writer Nicola Twilley Discusses Mummy Sleuths, the Hunt for the Ancient Microbiome, and Finding Humanity in the Past
In a recent interview, Nicola Twilley talks about her reporting that followed scientists from the Institute for Mummy Studies as they excavate and glean discoveries from paleofeces preserved in the world’s oldest salt mine, and how that story changed her perspective on humanity and the past. Twilley was a 2025 award winner of the National Academies’ Eric and Wendy Schmidt Awards for Excellence in Science Communications.
AI designs a novel E. coli killer
Using an AI model of their own creation that writes whole genomes, a team of Stanford scientists has engineered a novel bacteria-fighting phage. A new age of antibiotics could be on the horizon.
Trump tells donors, ‘We need to elect JD,’ as vice president weighs his future
Advisers say the remark doesn’t mean the president has settled on a preferred candidate in 2028 as he plays up a contest between JD Vance and Marco Rubio.
Viewpoint: Europe needs a new scientific contract
The White House's new science strategy should be required reading in the Berlaymont and every European capital.Not because Europe should copy it. Parts of it should concern Europeans deeply. But because it asks the question Europe has so far avoided while steadily losing ground in the global race for technological leadership.Europe already possesses many of the world's finest universities, scientists and research-intensive companies. It produces world-leading research in fields ranging from quantum technologies and biotechnology to climate science. Yet time and again Europe generates the scientific breakthroughs while others build the companies, industries and strategic advantages around them, particularly in digital technologies. Increasingly, we find ourselves regulating technologies whose underlying capabilities were developed elsewhere.This is not primarily a scientific failure. It is an institutional one.The settlement that shaped modern science policy emerged after the Second World War. In Science, the Endless Frontier, Vannevar Bush argued that governments should invest in fundamental research while protecting scientists from political direction. Public investment was justified precisely because no government, university or company could predict where the next transformative discovery would emerge.That scientific contract served liberal democracies extraordinarily well. It underpinned decades of advances in medicine, computing, energy and communications, but the world for which it was designed no longer exists.Artificial intelligence is transforming not only technology but the production of knowledge itself. Advanced chips, computing power, data and scientific instruments have become strategic assets. Scientific knowledge now diffuses globally almost instantly. Competitive advantage increasingly lies not in making discoveries first, but in possessing the infrastructure, capital, engineering capability and institutions required to translate those ideas into products, industries and strategic advantage.The old boundaries between science, industrial policy, national security and geopolitics have largely disappeared. Dual-use technologies now underpin both economic power and military deterrence.The US has recognised this shift. In July, the White House published Science: A New Golden Age, a comprehensive attempt to rethink the relationship between science and national power. The report builds on Bush's legacy, but departs from his framework in important ways. Science is no longer treated simply as the source of future discoveries. It is presented as the foundation of economic resilience, technological leadership and national security. AI, advanced infrastructure and the capacity to build become as important as discovery itself.Yet the report also reveals a striking paradox. The same administration calling for “a new golden age” of US science has simultaneously proposed deep cuts to the federal research enterprise while expanding political influence over the allocation of public research funding. Europe should therefore distinguish between the report's diagnosis and its prescription. The diagnosis, that science has become a strategic asset, is compelling. But the prescription is self-defeating. Long-term technological leadership depends on strong universities, academic freedom and the institutional autonomy that makes scientific discovery possible. This distinction matters. Bush's achievement was never simply to make science serve national strength. It was to establish a division of labour in which governments invested in research without attempting to direct discovery itself. Scientific breakthroughs emerge precisely because researchers retain the freedom to pursue questions whose value cannot yet be demonstrated and whose conclusions cannot be anticipated.Neither China, nor the USAs science becomes more strategically important, the temptation to politicise it inevitably grows. But scientific freedom is not an obstacle to technological leadership, it is an essential precondition.China represents the opposite model. For decades it has integrated science, manufacturing, infrastructure and industrial policy into a single national strategy. Its ability to mobilise resources around critical technologies is formidable. But it does so within an authoritarian system where scientific priorities are increasingly inseparable from political power.Europe should imitate neither model. It should learn from the strategic ambition of the US without importing its growing politicisation of science. And it should learn from China's capacity to build without adopting its concentration of power.Instead, Europe needs a scientific contract of its own. Bush's scientific contract protected the freedom to discover because the defining challenge of the 20th century was producing new knowledge. Europe's next scientific contract must preserve that freedom while ensuring that scientific discoveries can be converted into technological, industrial and strategic capability. Because in a transactional world, Europe's freedom to shape its own future depends on its capacity to build it.Related articlesThe US ‘golden age’ science strategy: what Europeans need to knowEuropean researchers sound the alarm that Trump rule changes will hit cooperationNIH turmoil risks reciprocal EU-US access to health research fundingThis does not mean subordinating free science to competitiveness or industrial policy. On the contrary. Scientific autonomy remains the first principle of Europe's next scientific contract. Governments should not direct scientific discovery. Their responsibility is to ensure that Europe's scientific, industrial, financial and regulatory institutions work together rather than in isolation.Meeting that responsibility requires far more than research funding. European researchers need access to world-class computing infrastructure, advanced laboratories, shared datasets and scientific facilities. Innovative companies need patient capital, testing environments and a genuine single market in which they can scale without facing 27 different regulatory regimes. Public procurement must evolve from purchasing existing technologies to creating markets for new ones. Regulators must become partners in experimentation rather than guardians of yesterday's rules.A connecting architectureEurope does not need to invent the Defense Advanced Research Projects Agency (Darpa) model from scratch. Britain's Aria, Germany's Sprind and Wellcome Leap already show that Europe can build institutions capable of taking high-risk, mission-oriented bets while preserving democratic accountability. The challenge now is not to create more isolated initiatives, but to connect them to Europe's broader scientific, industrial and financial system so that breakthrough discoveries can scale.Above all, Europe must stop treating research, innovation, industrial policy, finance and security as separate policy domains. The challenge is no longer to create excellent institutions in each of these fields, but to make them work as one European innovation system. Europe's strength will increasingly depend not on excellence within institutions, but on excellence across them.Europe's ambition should be neither to imitate the US nor to emulate China. It should demonstrate that scientific freedom, democratic legitimacy and technological capability are not competing objectives, but mutually reinforcing strengths. In an age of geopolitical rivalry, Europe's greatest advantage may ultimately be its ability to attract the world's best talent by combining scientific freedom, democratic openness and technological ambition.Bush's scientific contract helped define the 20th century because it protected the freedom to discover. Europe's challenge is not to abandon that achievement but to extend it. The defining task of Europe's next scientific contract is to preserve the freedom to discover while building Europe's capacity to translate scientific discovery into technological power.Kaare Nielsen is founder of Pomus, a Danish think tank on science and innovation.
Science|Business summer reads of 2026
As most people in the European research and innovation policy bubble are going on a well-deserved summer break, we have come up with a list of our favourite books, podcasts and essays from the past year that ask deeper questions about science, technology and politics.BooksPasteur’s Quadrant: Basic Science and Technological Innovation, by Donald StokesIf you haven’t read Pasteur’s Quadrant yet, now is the time. In the EU and elsewhere, we’re living through a period of dwindling faith that curiosity-driven research automatically leads to economic growth and technological progress. Pasteur’s Quadrant, published in 1997 by the Princeton academic Donald Stokes, is the most influential critique of the standard “linear model” of R&D: the idea that new discoveries made in ivory-tower labs get neatly passed on for commercialisation by start-ups. In reality, Stokes argues, practical applications often inspire more theorical lines of inquiry. Of course, we have long known that things are more complex than the linear model, but even today, it’s still often assumed in Brussels discourse. The book is a useful corrective, and is being used now to argue for new types of scientific institutions. David MatthewsThe Weaponization of Expertise: How Elites Fuel Populism, by Jacob Hale Russel and Dennis PattersonAre society’s problems solvable by technical expertise alone? “If only the benighted would listen,” say Jacob Hale Russel and Dennis Patterson, two professors at Rutgers Law School who got frustrated with how scientists and politicians handled public health communication during the Covid-19 pandemic. In the book, they argue that clichéd mantras about scientific evidence and expertise perpetrated by academics, journalists and politicians have harmed public trust in the very institutions they were trying to defend. Paradoxically, slogans such as “we believe in science,” “follow the science” and “defer to the experts” can fuel mistrust in science, experts and democratic institutions. The authors criticise “condescension” and “technocratic paternalism” in the public discourse and make the case for a more nuanced approach to scientific and expert policy advice that rests on humility, doubt, scepticism and open dialogue. “Most complex social questions in fact revolve around values, not the recitation of unambiguous facts,” they say. Florin ZubascuBreakneck: China's Quest to Engineer the Future, by Dan WangIn this book, Dan Wang compares the structural differences between the US and Chinese industrial policies, but raises a very timely question for innovation policy wonks: how can advanced manufacturing know-how contribute to technology-intensive economic growth? Wang says technology has three components: the tools, the blueprints and patents, and the process knowledge. The third component represents the “proficiency gained from practical experience, which isn’t easily communicated and requires years of implementation.” According to Wang, rather than seeing tools and blueprints as the ultimate ends of technological progress, policymakers should see them as milestones in the training of better scientists and manufacturers. Over the past decades, China has amassed “process knowledge” because capital flowed to complex fabrication facilities, while investors in the West have parked their money in capital-light businesses such as digital platforms or chip companies that focus on design. As it turns out, thanks to its oversized focus on manufacturing, China has gained remarkable advantages in the global technology race. Florin ZubascuBaltic: The Future of Europe, by Oliver MoodyWhat can Europe learn from the nine countries surrounding the Baltic Sea? Alongside the familiar stories about Estonia's digital transformation, the book examines how the region has used technology, resilience, education, governance and long-term thinking to respond to geopolitical, economic and security challenges. Innovation policy wonks might find fresh perspectives on how innovation can strengthen defence, societal resilience and Europe's capacity to adapt in an uncertain world. Whether or not you agree with all of Oliver Moody's conclusions, the book is a useful guide to a region that is increasingly shaping European debates on security, competitiveness and technology. Goda NaujokaityteThe Invention of Nature, by Andrea Wulf This book chronicles the wild and adventurous life of natural science pioneer Alexander von Humboldt who at some point in the 19th century seems to have been just about the most famous person in the world. Through scientific expeditions to the Andes Mountains and to the depths of Siberia, von Humboldt contributed a host of discoveries and concepts. During his life he met and formed relationships with historical figures as different as Johann Wolfgang von Goethe, Simon Bolivar, Thomas Jefferson, Napoleon Bonaparte and Charles Darwin. He is also claimed to be the person in the world with most things named after him, a list that includes an ocean current, a penguin and a region of the Moon. Still venerated in Germany, with numerous scientific institutions named after him, von Humboldt has slipped out of public consciousness in most of the rest of the world. For anyone not familiar with him, this book does a good job of describing his fascinating life. Ole EllekrogCareless People, by Sarah Wynn-WilliamsYou may have heard this referred to as the book Meta doesn’t want you to read. The 2025 memoir from Sarah Wynn-Williams, former director of global public policy at Meta, then just called Facebook, includes explosive claims about everything from a toxic workplace culture to how the company worked with advertisers to target vulnerable teens, and the lengths it was prepared to go to in order to break into China. It’s a fascinating insight into how and why the tech company gradually shifted its approach to policy, whether in the US, Europe or Asia. Meta has denied the allegations in the book, and last year won an emergency ruling to prevent Wynn-Williams from promoting it. In response, the author is now suing her former employer. If that doesn’t make you want to read it. Martin GreenacrePodcastsThe Europeans: Europe’s anti-ElonThis podcast is a great choice for a light-hearted dose of European policy and culture news. Most of it has little to do with research, innovation and technology, but this particular podcast features an interview with Mastadon’s founder Eugen Rochko. He talks about his experience running an open-source, federated, European-made social media platform, and leaving it all behind. The conversation, which starts 14 minutes in, gently encourages us to reflect on what kind of technology we, as Europeans, want to make. Goda NaujokaityteSolarpunk and how we escape dystopiaNew technologies are very often taken from science fiction. Alberto Santos-Dumont, inventor the airship, was inspired as a child by the adventure stories of Jules Verne. OpenAI’s attempt to build a personal assistant with the voice of Scarlett Johansson was lifted from the 2013 film Her, completely ignoring the movie’s cautionary message. So if we want better tech, we need to imagine it first. Unfortunately, the state of current sci-fi is relentlessly dystopian, giving inventors precious few ideas or hope. However, a new genre, Solarpunk, which envisages a technologically advanced but ecologically harmonious future, is now taking off. The actual tech the genre imagines, such as permaculture, renewable energy or community repair workshops, while nice, isn’t all that inspiring or ambitious. But it’s a first step towards rescuing sci-fi from its pessimistic Blade Runner rut. David MatthewsEveryday AbundanceLaunched in June, Everyday Abundance is a podcast that tells the stories of the inventions we now take so for granted that we barely given them a second thought. For example, the washing machine, which liberated women from a lifetime “bent over washtubs and washboards.” Or modern dentistry, which ended the reality that “tooth pain was simply part of human life.” Historians of technology, Virginia Postrel and Charles C Mann are very much on the optimistic end of the spectrum when it comes to the capacity of invention to improve human life. Here, they set out their case: if it wasn’t for progress, you might be hunched over a washtub with toothache rather than reading these words. David Matthews‘We will not know what we lost’: Conservation fallout a year after USAID shutdownSince his return to the White House, Donald Trump has been on a mission to undermine science. He slashed jobs at federal agencies, terminated grants in some research areas, took unprecedented control over university affairs and, within hours of his inauguration, suspended the US Agency for International Development. While its initial focus was to administer health and food aid around the world, it had since expanded to conservation projects. The result? Some of these projects were stopped abruptly. In this Mongabay podcast, environmental reporter Michelle Nijhuis tells the story of the EcoGuard conservation programme in Liberia, whose local patrols had helped protect rainforests, monitor endangered wildlife and track illegal threats. From one day to the next, these were left without salaries. Luckily, she notes, the initiative was able to get emergency funding from international NGOs, but its future remains “incredibly uncertain.” Juliette PortalaEssaysThe Mars Delusion, by Henry WismayerWhy is humankind so fixated on establishing a colony on Mars? asks London-based writer Henry Wismayer. From space evangelists promoting Martian settlement as an insurance policy, to billionaire Jeff Bezos, who said humans should settle on Mars “because it’s cool,” the mission is not running short of advocates. However, in this essay, Wismayer reminds us that some critics expect any future Mars pioneer to end up “irradiated, sick, mad and dead.” Scientists have already looked into the possible effects of prolonged exposure to Martian gravity, and it’s not pretty: muscle shrinking, bones weakening, changes to the central nervous system and other biological modifications to make us all reconsider the journey. “Some researchers have forecast that the future settler, after generations of evolutionary conditioning, will look less like an Übermensch and more like ET,” Wismayer writes. Juliette Portala
Miliband says reopening Strait of Hormuz 'essential' as he meets Rubio
The move is required "to ease cost-of-living pressures", Miliband says, as he meets his US counterpart in Washington.
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce Biotech has learned. The trial, which began only back in April, was a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score following treatment with SAR445399 compared with placebo in adults aged 18 to 80 years with NCFB, a chronic lung disease. The trial was officially reported as halted on July 29, the day before Sanofi’s second-quarter earnings call. The decision to pause the trial was made “as part of a company-wide portfolio review for strategic business reasons,” and not due to safety concerns, a Sanofi spokesperson told Fierce. The move to pause the NCFB trial comes during a trying time for Sanofi following a year filled with a series of trial fails. In February, the French pharma ousted CEO Paul Hudson and appointed Merck KGaA leader Belén Garijo, M.D., Ph.D., to steer the ship. Since then, Garijo has been doing a deep dive on correcting the company’s strewn R&D and clinical strategies. On July 24, Sanofi scrapped amlitelimab for atopic dermatitis, despite its lore as being a potential $5 billion blockbuster. During its second-quarter report, the company abandoned two more assets, balinatunfib and itepekimab, following failed trial results in psoriasis and chronic obstructive pulmonary disease, respectively. SAR445399, only first revealed by Sanofi in 2023, is an anti-interleukin-1 receptor 3 monoclonal antibody developed to block the interleukin 1, 33, and 36 cytokine pathways. These pathways can be important in chronic immune-related dermatologic diseases, such as atopic dermatitis and hidradenitis suppurativa, as well as respiratory conditions, such as NCFB. Related Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues NCFB affects roughly half a million people in the U.S., with a global incidence of greater than one million cases. In August 2025, Insmed received FDA approval for Brinsupri, a DPP1 inhibitor targeting neutrophil activation, for treatment of NCFB in adults and kids ages 12 and older. The British biotech Infex Therapeutics showed promising NCFB phase 2a data using their monoclonal antibody, INFEX702, which acts by disabling Pseudomonas aeruginosa, a bacteria known to be a major pathogen of NCFB. Sanofi is currently running a separate phase 2 study testing SAR445399 as a potential treatment for the inflammatory skin condition hidradenitis suppurativa.
Swallowing faecal capsules reduces peanut allergy in six adults
Altering the gut microbiomes of people with peanut allergy using faeces donated from an allergy-free individual improved their peanut tolerance in a clinical trial
ECU Health Medical Center begins using rapid blood culture testing tool
ECU Health Medical Center has announced that they are the fifth institution in the nation to begin using the BioMerieux Vitek Reveal analyzer, a rapid blood cul
Scientists use gene editing to create hypoallergenic dogs
Scientists at a biotech company have used gene editing to create two hypoallergenic beagles that don't trigger allergies.
Does Welbeck's exit offer hope to youth?
On the latest Albion Unlimited podcast, BBC Radio Sussex's Johnny Cantor is joined by former Seagulls forward Warren Aspinall as they discuss Danny Welbeck's decision to join Chelsea. Aspinall said he was "gutted" to see Welbeck leave Brighton after the 35-year-old spent over five years at the club.
F&M Brewing Science
Rob Jinks, professor of biology, who teaches the Brewing Science class at Franklin & Marshall College, dispenses a New England Indian Pale Ale into a pitcher inside Fair Trade Cafe
NEC Transfers Overseas Network Equipment Resale Business and Other IT Businesses
NEC Corporation (NEC; TSE: 6701) today announced that it has entered into an agreement with a consortium led by Assist Group S.r.l. with business leaders who have extensive experience across a wide range of industries to transfer its overseas network equipment resale business—which involves building systems for overseas telecommunications operators and enterprises using network equipment from partner companies—as well as its IT services business for governments and local authorities in certain countries, which includes system development for biometric authentication and smart cities.
The Beauty Of Settled Science
Commenters convinced me I made a subtle mis-step in my framing of Psychology Research Is Mostly Fine. My framing emphasized that social priming studies had failed to replicate, but that many other subfields of psychology hadn’t. This naturally led commenters to point to failed replications in other subfields. Although none of these were as bad as social priming, few or none were entirely problem-free. Instead of emphasizing the difference between social priming and other subfields, I should have emphasized the difference between settled science and novel research. Here are some of my favorite psychology findings: The brain is sculpted by reinforcement learning, and a key driver of this learning is a prediction-error-based algorithm located in the nucleus accumbens and implemented through dopamine. Psychedelic drugs exert their effects through 5-HT2A receptors, pointing to a role for these receptors in some sort of construct like the balance between priors and new evidence. Certain cognitive functions are localized to certain brain areas (for example, impulse control to the frontal lobes; linguistic structure to Broca’s area, linguistic meaning to Wernicke’s area. But injure one of these areas, or render a certain function useless (eg a blind person having no more use for their visual cortex), and these mappings can gradually shift - suggesting that neurons are general-purpose compute whose specialization is a contingent fact about convenience and efficiency rather than a necessity. Most personality traits and general capabilities are about 50% genetic and 50% random, with little role for family environment or childhood history, with a few notable exceptions like partisan preference. Recent research complicates this story, but the further you go from this basic picture, the gnarlier the chains of indirect causation you require. Neurons fire together in “brain waves”, whose exact frequency corresponds with the character of consciousness; These divide neurons into natural subpopulations and linked graphs. The gamma rhythm corresponds surprisingly well to items in conscious awareness. GABA receptors seem to be involved in something like relaxation. By hitting different GABA receptors in different ways, you can modulate the exact type of relaxation you produce. Hitting GABA-A directly is too powerful and can cause dangerous levels of sedation, but allosteric modulation of GABA is an incredibly fruitful strategy that underlies drugs from benzos to barbituates to alcohol. If you know your GABA-A subunits, you can target specific subtypes of relaxation; for example, Ambien hits GABA-A1 and induces sleep. Memory divides somewhat fuzzily into bins of immediate-sensory, short-term, and long-term, with separate retrieval and storage functions, and separate systems for declarative vs. procedural learning. These can be harmed selectively, usually by hippocampal injury, so that some patients can remember their life stories but not form new long-term memories, or learn new skills like bike-riding but not new facts. The exact substrate of memory is unclear but seems to involve new synaptic connections between neurons in at least some way. The ability of modern psychology and psychiatry to treat mental illness is real but limited. SSRIs work for half or slightly fewer than half of patients; antipsychotics work with extreme side effects; benzodiazpines work but produce addiction and tolerance in many (not all) people. Most supplements are stuck in Poor Quality Study Replication Crisis Hell, but melatonin and l-theanine stand out as especially promising. Psychotherapy works with moderate effect size, but (with a few exceptions) seems to be more about the relationship with the provider than the details of the therapy itself. Mental hospitalization can sometimes defuse immediate crises but work less well than mental hospitals would like, with some studies showing overall negative effects. Schizophrenia is mostly genetic, but risk also increases with prenatal infection (especially rubella) and obstetric complications; there is suggestive evidence for roles of social stress and drug use (with psychedelics and marijuana making things worse, and nicotine if anything making things better). Bipolar and schizophrenia are so closely linked on a pathophysiological level that it seems like they might be the same disease; on the clinical level, they do seem to follow two separate courses/prognoses but can sometimes surprise clinicians by eg someone who seemed condemned to permanent schizophrenia unexpectedly recovering. The brain’s native reinforcement learning algorithms cash out in the phenomena of classical and operant conditioning; different reinforcement schedules reinforce at different levels, which can be exploited by bad actors to make especially compelling products (eg slot machines). None of these are immune to doubt. A few are speculative; one or two are genuinely unorthodox. But they’re all a step above one p = 0.049 paper that might not replicate. If they get overturned, they’ll be overturned by the same sort of genuine scientific shift that replaced Ptolemy with Copernicus or Lamarck with Darwin, not some sort of sordid discovery about someone entering random numbers into a spreadsheet. In 2008, Eliezer Yudkowsky wrote about The Beauty Of Settled Science: If you only care about scientific issues that are controversial, you will end up with a head stuffed full of garbage. The media thinks that only the cutting edge of science is worth reporting on. How often do you see headlines like “General Relativity still governing planetary orbits” or “Phlogiston theory remains false”? So, by the time anything is solid science, it is no longer a breaking headline. “Newsworthy” science is often based on the thinnest of evidence and wrong half the time—if it were not on the uttermost fringes of the scientific frontier, it would not be breaking news. Scientific controversies are problems so difficult that even people who’ve spent years mastering the field can still fool themselves. That’s what makes for the heated arguments that attract all the media attention. Worse, if you aren’t in the field and part of the game, controversies aren’t even fun. Don’t be embarrassed to read elementary science textbooks, either. If you want to pretend to be sophisticated, go find a play to sneer at. If you just want to have fun, remember that simplicity is at the core of scientific beauty [...] A steady diet of science news is bad for you: You are what you eat, and if you eat only science reporting on fluid situations, without a solid textbook now and then, your brain will turn to liquid. Psychology isn’t centrally the new paper in Annals Of Recently-Breaking News saying that an n=5 study showing that large portion sizes increase support for terrorism. Psychology is centrally ideas like brain waves, GABA receptors, reinforcement learning, twin studies, and connectionism. People who think differently are worrying too much about BREAKING NEWS!!!, and should stop. The key distinction isn’t “recent research in social psychology” vs. “recent research in cognitive/bio/behavioral psychology”, as my essay last week unfortunately implied. It’s recent research in general vs. the deposit of settled science, battle-tested hypotheses, and carefully-earmarked speculation. And part of the reason social priming in particular was such a disaster was that it defied that heuristic, building itself up over hundreds of studies until it approached or even entered the pantheon of settled science - before collapsing (5-HTTLPR was also sort of like this). This isn’t a claim that settled science is always right - Freud was “settled science” for a long time - just that there’s an intuitive distinction between the level of credence you should have in the existence of power posing vs. the existence of Broca’s Area. (I compounded this error by calling the last post “Psychology Research Is Mostly Fine”, which suggested I was talking about the new research rather than the settled science. I actually meant to distinguish between research-psychology-the-field vs. clinical-psychology-aka-therapy, but this framing unintentionally pushed against the point I wanted to make) Some commenters on the previous article understood this point, but challenged its weight. It’s very cool, they said, to know how many neurons are in which brain lobe, but the main way that Psychology affected their lives was through bad clickbait studies used to buttress dumb policies; some p = 0.049 study says that exposure to microaggressions makes minorities’ brains shrivel into raisins, and now their company has to implement punitive DEI or be sued for hazardous work conditions. I won’t dispute this as an accurate description of how the sausage gets made, but it’s worth examining the trains of thought that connect this observation to a campaign against psychology in general: The dumb woke psychology was wrong and bad, and I don’t have good heuristics for distinguishing dumb woke psychology from other psychology, so I’m going to assume it’s all wrong and bad. The dumb woke psychology was wrong and bad; it seems useful to punish/discredit psychology as a whole to assist my campaign against it, so for propaganda purposes I will try to discredit psychology as a whole. To people in the first camp, my response is: come on, your heuristics aren’t that bad. “Microaggressions makes minorities’ brains shrivel up like raisins” is in the woke category; “the hippocampal theta rhythm seems to be associated with both memory and pathfinding, suggesting an unexpected yet surprisingly compelling relationship between the two” is in the not-woke category, don’t play dumb here. To people in the second camp, my response is: deliberately exaggerated propaganda campaigns are bad and this is a confession, not an excuse. Inability to view science through anything but a political lens was what got us into this problem; doubling down on it is a temporary solution but a recipe for permanent disaster. If you pronounce entire fields of science to be acceptable collateral damage in your campaign against bad political actors, you will alienate not just scientists but patients, clinicians, and general lovers of truth. Instead, you can say the thing you mean - that woke partisans shouldn’t try to occupy and exploit the otherwise-noble science of psychology for their own political gain - and wage the same campaign with a halo rather than a comic-book-villain goatee. From the font of oracular wisdom that is Weird Sun Twitter: [ Vessel Of Spirit@VesselOfSpirit i love you all conditionally but i love the good part of you unconditionally. even if it becomes a very small part 2:11 AM · Jan 22, 2015 1 Reply · 5 Reposts · 29 Likes ](https://x.com/VesselOfSpirit/status/558084551772471298) This is how I feel about psychology1, too, but with a touch more optimism. The good part of psychology is enormous, a hoard of endless treasures. You just have to look past the headlines! 1 To play devil’s advocate - should one always be so magnamious? Astrology? Phrenology? These seem different in that their entire orientation was flawed from the start; they didn’t simply fail to find the correct constellation-personality connections, the whole project of searching for connections between constellations and personality was doomed from the start. More difficult might be asking the same question about education research, which is notoriously bad. I don’t know enough about education research to know if there’s some settled science of correct and enlightening results lurking in the background beyond the day-to-day froth of poorly-conducted and politically-motivated studies. I think if it’s 90% bad, 10% good, it’s correct to call it bad as a compact way of communicating a useful truth; I think psychology is better than that, but admit it’s a tough judgment call.
Emory biophysicist Shashank Shekhar’s research into tiny cellular force generators nets two major federal awards
Emory assistant professor Shashank Shekhar has been awarded $3.5 million in funding for his innovative research focused on how biochemical interactions influence actin, the vital protein responsible for cell structure and movement.
Fidji Simo had to leave OpenAI. But she’s still building a business that could find cures to chronic diseases that affect women like her
ChronicleBio is using AI to improve clinical trials and find cures for diseases like POTS.
ADM raises 2026 outlook as biofuels drive growth
The Chicago-based company’s second-quarter adjusted earnings also handily beat analysts’ expectations.
MrBeast Sales Slow, Angel Stock Falls, MUBI and Neon Look for Hits, and Will an NBA Franchise Set a Sales Record?
(Welcome to the Entertainment Strategy Guy, a newsletter on the entertainment industry and business strategy. I write a weekly Streaming Ratings Report and a bi-weekly strategy column, along with occasional deep dives into other topics, like today’s article. Please subscribe.) You probably remember egg prices spiking a few years ago. This led to a lot of debate between the pro-market/pro-competition/antitrust/Neo-Brandesian crowd and the center/center-right/center-left/abundance/libertarian crowd over the cause, whether it was the avian flu outbreak or whether industry consolidation led to price fixing, using avian flu as a convenient cover. Basel Musharbash wrote a whole investigation at BIG looking at it. Well, two years later, we have our answer: it was price fixing. The Justice Department found proof, via emails, of price fixing. Indeed, just the threat of an investigation brought prices down two years ago: I bring this up because at least half a dozen of my favorite political writers and pundits, who were skeptical about price fixing at the time, haven’t written any mea culpas on this issue. It’s really dispiriting and makes it much, much harder to trust their work on other issues. If you take a hard stand on an issue, then you get it wrong, you need to explain how and why you got it wrong. Or update your priors. This is how epistemological bubbles are formed! All of which is to say, it’s time for another installment of “What I Got Right, What I Got Wrong”. Last issue, I mostly focused on the “wrong” side of the equation, so today’s is a bit more balanced, but with one big mea culpa (though I still stand by my original concerns). Let’s dive right in! Subscribe CORRECTION: UFC Didn’t Release Subscriber Data (But Seems to Have Bragged About It Internally) In my analysis of the viewership of UFC Freedom 250, I wrote... “Paramount has also released datecdotes bragging about their subscriber numbers. Earlier this year, they claimed that the first UFC fight on Paramount+ brought in 1 million subscribers.” Well, that datecdote did not come from a PR rep, but from great reporting from James Faris at Business Insider. The actual quote was this: “Paramount’s flagship streaming service generated about a million new subscribers on the day of its first-ever UFC event, Paramount product chief Dane Glasgow told employees in a town hall on Tuesday morning, three staffers who attended the meeting told Business Insider.“ This wasn’t the biggest goof in the world; even Faris emphasized to me that this is more a “clarification” than a correction. Still, it sounds like, internally, the folks at Paramount were very happy about this result—and I’m guessing they were happy with this news getting out—even though the gains didn’t last through the quarter, dropping to 700K adds. RIGHT: MrBeast’s Struggles Continue... I’m very skeptical about MrBeast’s burgeoning media “empire” and, in particular, its $5 billion valuation, as I wrote earlier this year and last year. Sure enough, according to Business Insider, regarding its “booming” consumer products division_:_ “US sales volume grew 13% year-over-year in 2025, following a 33% leap the previous year, according to a presentation deck dated May 2026....A February 2025 investor deck viewed by Business Insider showed Feastables’ net revenue more than doubled in 2024 from 2023, to $215 million, and was forecast to grow 74% in 2025, to $375 million.” [Emphasis mine.] If you told investors that you projected 74% growth but delivered 13%,1 that’s not ideal. But it’s not just MrBeast. Logan Paul and KSI’s Prime had sales drop in half for their energy drinks. It’s one thing to build a successful entertainment company and an entirely different thing to succeed in the heavily-consolidated-but-also-very-competitive consumer packaged goods space! CPGs are dominated by a few firms with very wide moats compared to YouTube, which has few barriers to entry. These businesses require different skill sets and have completely different business environments. WRONG: Does the NBA Have an $8 Billion Bidder? Almost as soon as I published my article about the NBA’s finances, casting skepticism on NBA expansion, I saw this Front Office Sports headline: One group “claims to have already raised $8 billion” for the Vegas expansion team. I mean, wow. That’s just $2 billion less than what the Los Angeles Lakers were valued at when they were sold just last year. And they’re arguably the most popular team in the NBA. (Side note: the new owner is now under an investigation for fraud in how he went about financing the Lakers and the Dodgers purchases.) So much for the “dried up” language I used in that article. (This is why I usually stick to my “Entertainment Nuance Guy” tone in articles...) I went off old information—from April, when I read/heard about the NBA downplaying expansion efforts—instead of doing a quick double-check for new news. That said...if you read the article, the market for Seattle is “slow”, with just one reported bidder. So I wasn’t entirely off. This goof has annoyed me since I first published it, mainly because it undercut that article’s real point, which I stand by: NBA franchises are really overvalued right now. Now, I get why NBA teams are overvalued. When it comes to owning sports teams, it’s basically never wrong to assume that some rich person somewhere will care more about owning a team (or just being part of a group since they’re so expensive) than the actual financials. There are only so many teams to own, and opportunities to buy in preferred markets don’t come along very often. This explains why the teams sell for such high multiples (usually above a 10 to 12.5 revenue multiple, which is very high). You only need one person to overpay! Beyond the ultra-wealthy luxury good explanation, I worry NBA teams are becoming speculative assets. More and more private equity investors are buying into NBA teams. But the value, in owning a team, comes from selling it later, not any meaningful relationship to revenue or profit growth. In other words, the newer NBA owners are increasingly expecting someone later to buy their inflated asset. That’s not sound economics; that’s the “greater fool” theory at work.2 At some point, actually making money has to matter. Especially since revenue growth is now below the growth of the stock market. (And this matters because the NBA doesn’t have easy levers to pull to drastically lower their costs—half of their revenue has to go to players and then you actually have to run a team, including coaching, training, travel, media expenses, and more—or raise revenues aside from one-off expansions in America and overseas.) I just don’t see how investors make their money back buying NBA teams, except for selling at a higher price later on down the line. But if revenue/profit growth continues to slow, at some point, someone will be left holding the bag. RIGHT: Baseball and Basketball are about equally popular. Related to the above, I wanted to cite two quick pieces of evidence for one of my other theories: that the NBA and MLB are about as popular as each other, but the NBA gets much, much better media coverage. One YouGov survey has that fans prefer basketball to baseball by 52% to 48%, which I’m guessing is within the margin of error for that poll. That’s virtually even, meaning they’re about the same popularity. Over on NBC, a recent Red Sox-Yankees game averaged 4 million viewers, higher than Sunday Night Basketball’s average of 3.4 million on the same network. A Yankees-Dodgers game averaged 3.9 million two weeks ago. Not every game averages this much, but it shows you that baseball isn’t far off from basketball, depending on the matchup. Altogether, the NBA is just slightly more popular than baseball, but NBC is paying MLB a fraction of what they pay the NBA, a point I’ve made before. RIGHT: Angel, MUBI and Neon Updates... I’ve long been skeptical about many of Hollywood’s buzziest startups/smaller indie studios. It’s not that they don’t make great movies—films like Anora and Everything Everywhere All at Once are amazing—or that they’re not (rightfully) pushing the majors to make better films, but...they get a ton of hype, and that hype often doesn’t live up to the reality or difficulty in scaling up. Starting with MUBI, well, The Wall Street Journal wrote a feature on MUBI’s struggles last April, best summarized by the subheader “After Sequoia valued Mubi at $1 billion, a left-wing revolt sent the indie film company into a tailspin”. MUBI lost $7.3 million on $200 million in revenue in Q4 2025, but reportedly hit a record 1.7 million subscribers at the end of Q1. As for Neon, Department M purchased a “significant stake” in the company earlier this year. How much is that “stake” worth? According to Deadline, “No financial figures for the Neon-Department M deal were disclosed.” So...that’s not great! If it was a big valuation, we’d hear about. Also, I found this curious: “Both Neon and Department M already have separate partnerships with Qatar. The Qatar Film Committee has a slate deal in place with the former, and a biopic production pact with the latter.” Color me skeptical about much Middle Eastern investment dollars. See: LIV Golf. Finally, as for Angel (formerly Angel Studios), their stock very, very slightly popped last month after Young Washington ($20 million budget) which made $45 million in the US, but their stock is still way down from its opening. Smaller Updates RIGHT: The WGA should focus on antitrust concerns! I’ve been on this for years. Post-WGA/AMTPT deal in 2023, I wrote an article for the Ankler calling on the WGA to focus and organize against industry consolidation. Sure enough, the WGA filed a lawsuit against the Paramount-WBD merger, and people are organizing around this issue now. I wish this energy had coalesced earlier (specifically to lobby Washington much earlier), but better late than never! WRONG: Actually, the chip shortage might be due to market manipulation. In my last “Long Reads for the Long Summer” article, I shared an article about how LLMs are causing memory chip prices to spike, which will make all electronics more expensive. Well, turns out, three RAM manufacturers control 90% of the market, and now a private lawsuit accuses them of price-fixing. So yeah. WRONG/UPDATE: The Odyssey will hold! Two weeks ago, I wrote, “As of this moment, we haven’t had a super-blockbuster, though The Odyssey, Spider-Man: Brand New Day and Avengers: Doomsday could all cross the $500 million mark. (At this point, The Odyssey would need a very strong hold to get there.)” Well, it’s safe to say it’s going to have that hold! It only dropped 30% in weekend two and IMAX screenings are sold out all month. Spider-Man: Brand New Day is also off to a great start. RIGHT: People are rushing to get shows out yearly. I’ve long been bullish on yearly, weekly-released shows, and Leslie Goldberg at The Ankler wrote about how many people in town are now listening. WRONG: Mark Carney reverses Canada’s stance on homegrown production. After writing about Canada installing domestic production quotas, Canada has backed off. WRONG: I don’t trust Spider-Man: Brand New Day’s online “views”. When I originally wrote about the latest Spider-Man film’s record-breaking trailer, I thought this was just YouTube views, but after watching this Corridor Crew video and doing more research, well, it’s all social views of the trailer globally. Really? That stat includes TikTok, Reels and YouTube Shorts views. Basically, I don’t trust it anymore. (This film will probably set record, but I trust the pre-sales data more.) RIGHT: Celebrity Production companies are still struggling. I’ve written about this for years, but the company that I didn’t track was Kevin Hart’s HartBeat, which was valued at $650 million but is struggling now and might just end soon, especially after Kevin Hart pulled his endorsement deals. And Bad Robot is moving to NYC. CORRECTION: SpongeBob is a “second run” title. In my 2025 recap article, I had _SpongeBob SquarePants_labelled as a “library” title, when it is still a “second run” show, with new episodes still coming out on Nickelodeon. CORRECTION: In my last “What I Got Right, What I Got Wrong” update, I offered a correction from Doug Creutz and misspelled TD Cowen. Thanks, Grammarly! 1 Though he could have increased prices to make up for the gap, he couldn’t have increased them that much. 2 There’s a theory, which I think that Daryl Morey created and Bill Simmons popularized, that, to be successful building your team, you only need a handful of bad GMs in the league to take advantage of. To be clear, Daryl Morey’s theory was also for signing bad contracts, that you could always get out of bad contracts. Basically, there’s always someone who will make a bad trade. It’s not the same exact thing, but similar enough to the Greater Fool Theory that I really like it.
Emory biophysicist Shashank Shekar’s research into tiny cellular force generators nets two major federal awards
Emory assistant professor Shashank Shekhar has been awarded $3.5 million in funding for his innovative research focused on how biochemical interactions influence actin, the vital protein responsible for cell structure and movement.
What to Eat and What to Avoid for Optimal Gut Health
Gut health can impact everything from sleep to the immune system, so Dr. Roshini Raj, associate professor of medicine at NYU Langone Health, shares her recommendations for preserving your gut microbiome. She shares the signs of an unhealthy gut, and what to eat to improve it. Dr. Raj also shares her tips for avoiding cyclosporiasis.
UT San Antonio scientist highlights growing threat of antifungal resistance
For decades, scientists have studied antibiotic resistance, which is how bacteria evolve mechanisms to evade lifesaving drugs. Now, researchers are warning that a similar challenge is emerging among fungi, where resistance to frontline antifungal medications is making serious infections increasingly difficult to treat. Nathan Wiederhold, PharmD, director of the Fungus Testing Laboratory and professor […]
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing...
What Bifidobacteria tell us about gut health and how diet can help
In this interview, microbiome researcher Sudarshan Shetty explains what shapes Bifidobacteria, how they change with age, and what diet can do
BP Puts Another Asset Up for Sale as Profit Surges
BP to sell biogas business; HSBC resumes buybacks
BP to sell US biogas business as profits soar
Chief executive says UK oil major has had several approaches for its North Sea assets
UMass Chan receives Massachusetts Life Sciences Center funding to advance health equity in pregnancy care and biomedical discovery
UMass Chan Medical School researchers have received funding from the Massachusetts Life Sciences Center to advance research using artificial intelligence to improve early identification of pregnancy-induced hypertension and to establish a colorectal cancer biobank that will accelerate biomedical discoveries.
Ocular Therapeutix Reports Second Quarter Revenue, Provides Business Highlights
BEDFORD, Mass.—Ocular Therapeutix, Inc. (NASDAQ: OCUL), an integrated biopharmaceutical company in the retina space, has reported financial results for the second quarter ended June 30, 2026, and provided recent business highlights. Total net revenue was $13.5 million for the second quarter of 2026, flat as compared with the same period in 2025. The company also reported a net loss of $78.8 million for the quarter, compared with a net loss of $67.8 million for the comparable quarter of 2025.
Jackie the eagle faces health complications as anemia worsens despite transfusion
KMPH Fox 26 is the Central Valley's news leader, covering Fresno, California and the surrounding area, including Clovis, Madera, Hanford, Visalia, Biola, Kerman, Tranquillity, San Joaquin, Reedley, Coalinga, Avenal, Lemoore, Tulare, Selma, Caruthers, Tollhouse, Three Rivers, Porterville, and Merced.
Educator and business expert gives tips to young and emerging entrepreneurs in Milwaukee
In honor of National Black Business Month and World Entrepreneurs’ Day on Aug. 21, Angelique Sharpe shares how emerging entrepreneurs in Milwaukee can develop a successful business.
Acoustirats and Jordan Lauterbach to Perform at LI Music & Entertainment Hall of Fame on Aug 23rd
As part of the Long Island Music and Entertainment Hall of Fame Soundtrack to Summer Series, the band Acoustirats will perform LIVE music and Comedian Jordan Lauterbach will open with comedy set at the Long Island Music and Entertainment Hall of Fame in Stony Brook Village (97 Main Street, Stony Brook, NY) on Aug. 23th from 3-4pm. The event is free for members or with general admission ticket purchase or $10 at the door concert ticket purchase. For details on this and upcoming events please visit https://www.limusichalloffame.... About AcoustiRats AcoustiRats is an acoustic duo dedicated to stripping Good Rats classics down to their raw, essential form. Fronted by Stefan Marchello, lead singer and 36-year veteran of the Good Rats, alongside guitarist Matt McCarthy, who also did a run on guitar with the band. Between them, they've got decades of Good Rats DNA in their blood. After years of playing these songs loud and electric, Stefan and Matt are thrilled to break them down to the bare bones. No frills, no amps cranked to 11 — just voice, acoustic guitar, and the songwriting that made the Good Rats legendary. It's the same attitude and stories fans know, delivered in a raw, intimate format. For diehard Good Rats fans, it's a new way to hear the classics. For first-timers, it's proof that great songwriting doesn't need to be loud to hit hard. About Jordan Lauterbach Jordan Lauterbach is a fast-rising comedian who features prominently in clubs around the country. His autobiographical style and supreme wit keep audiences laughing for hours after they leave the club. Lauterbach is likable, relatable, and tremendously funny. He has opened for some of comedy's best and is quickly carving out an audience of his own.
Exclusive: Former OpenAI exec Fidji Simo discusses her battle with POTS and her startup’s plans to cure it with AI and 3,500 vials of blood (so far)
Simo is a cofounder of ChronicleBio, which aims to cure complex chronic diseases by analyzing biological data with the latest AI models.
Upcoming Science Cafe
BAR HARBOR—Join us for a fascinating Science Cafe with environmental toxicologist Nishad Jayasundara, Ph.D., as he explores how everyday contaminants and other stressors such as heat exposure may be quietly influencing kidney health. Chronic kidney disease (CKD) affects nearly 1 in 7 adults in the United States—and more than 840 million people worldwide. While factors like diet and genetics are well known, scientists are increasingly uncovering another important piece of the puzzle: environmental exposure. Drawing on his team’s research, Dr. Jayasundara, Maine INBRE alum as a College of the Atlantic undergraduate student and past MDI Bio Lab Visiting Scientist, will share how early-life exposure to environmental toxins can disrupt kidney development, and may affect kidney structure and function in adults. Blending cutting-edge research with real-world relevance, this Science Cafe will shed light on an important and often overlooked contributor to human health—and what it could mean for communities around the world. Monday, August 17, 2026 at 5 p.m.Hybrid event at Maren Auditorium and via Zoom Register Now What Are Science Cafes? MDI Bio Lab’s Science Cafes provide an informal introduction to ground-breaking biomedical research by its scientists, scholars from near and far and from local experts in other fields as well. Each Cafe lasts about one hour; the floor is open for questions and discussion. It can get lively and it’s always engaging. MDI Science Cafes are open to the public and free of charge. For more information, or to watch past events, visit our website. The MDI Science Cafe Series is brought to you by Cross Insurance. Subscribe Share Leave a comment
The computer science major is dying so that the AI literacy minor can be born: ‘we have to democratize it’
Computer science enrollment is falling even as psych, music and biology majors rush into AI minors — colleges are racing to keep up with employer demand.
UT San Antonio scientist highlights growing threat of antifungal resistance
For decades, scientists have studied antibiotic resistance, which is how bacteria evolve mechanisms to evade lifesaving drugs. Now, researchers are warning that a similar challenge is emerging among fungi, where resistance to frontline antifungal medications is making serious infections increasingly difficult to treat. Nathan Wiederhold, PharmD, director of the Fungus Testing Laboratory and professor […]
As the GLP-1 Era Reshapes Weight Management, METAbiotics Launches with Science Designed to Support Long-Term Success
Today, Danone subsidiary The Akkermansia Company announced the U.S. launch of METAbiotics, a science-backed postbiotic brand developed from decades of pioneering research into Akkermansia muciniphila and designed to support sustained weight management and metabolic health.
As Global Land Degradation Accelerates, WCS Brings Science and Wildlife Conservation Expertise to UNCCD COP17 in Mongolia, August 17-28
ULAANBAATAR, Mongolia, August 3, 2026 — As land degradation, biodiversity loss, and climate change increasingly threaten ecosystems and communities around the world, the Wildlife Conservation Society (WCS) will urge governments at the 17th Conference of the Parties to the United
As Global Land Degradation Accelerates, WCS Brings Science and Wildlife Conservation Expertise to UNCCD COP17 in Mongolia
ULAANBAATAR, Mongolia, August 3, 2026 — As land degradation, biodiversity loss, and climate change increasingly threaten ecosystems and communities around the world, the Wildlife Conservation Society (WCS) will urge governments at the 17th Conference of the Parties to the United
Decoding the gut microbiome's symphony in health and disease
The trillions of microorganisms living in our intestine influence our health, from digestion and metabolism to immunity. Yet scientists still struggle to understand how these microbes shape these important physiological functions because gut microbiomes are extraordinarily complex, redundant, and dynamic. New technologies are therefore essential for advancing microbiome research. Researchers at the University of Vienna have now reported effective strategies for simultaneously measuring thousands
Let’s do science: Share your wild turkey sightings
MAINE—All good wildlife management starts with science, and all good science starts with data. That’s where you come in. Maine’s Wild Turkey August Production Survey invites community scientists to play a direct role in monitoring our state’s wild turkey population. Whether you enjoy watching wildlife from your window, spend time hiking, hunting, or exploring the outdoors, or just need an excuse to get outside, you can help. Each summer, Maine’s wild turkey hens are busy raising the next generation of birds. By reporting your sightings and observations, you’ll help our biologists monitor annual reproduction rates, track population trends, and make informed management decisions that support healthy, sustainable turkey populations for generations to come. The information collected helps ensure there are abundant opportunities for both wildlife watchers and hunters to enjoy Maine’s wild turkeys. It’s easy to participate! Whenever you see wild turkeys anywhere in Maine during August, simply report: Date and location of your observation Number of adult females (hens) Number of adult males (gobblers) Number of poults (young turkeys) Estimated poult size relative to the adult hens Every observation counts, even if you don’t see poults. Together, these reports provide a clearer picture of turkey productivity across the state and are an important part of Maine’s wildlife management. Ready to help? Report your turkey sightings online using the Wild Turkey August Production Survey. Submit an Observation Subscribe Share Leave a comment
Senate Panel To Examine Biotech's Role in U.S. Health Resilience
Senate Finance Committee investigates biotech's impact on U.S. health resilience as China gains pharmaceutical advantage. Hear expert testimony August 4.
'The apparent chaos of the Anthropocene is turbocharging evolution itself': Plants are finding ways to survive and thrive in the climate crisis
In this excerpt from "Despite it All," author Fred Pearce explores the ways plants are adapting and evolving in the face of climate change — and how we need to recognize this reality and foster its potential boost to biodiversity, rather than holding steadfast to our notions of what types of nature should and shouldn't be allowed to thrive.
Stephanie White, let me 'educate' you on the science of why men don't belong in women's sports
Stephanie White said she wasn't educated enough on the science of males in women's sports. Here's what biology and sports science say about fairness.
Science filled BioBus set to make stops in Capital Region to promote STEM and learning
Chile declares health alert for hantavirus
The Chile Ministry of Health issued a Health Alert for hantavirus and other diseases, such as some arboviruses and avian influenza. This is the first time this measure has been taken and it will be in effect until July 31, 2027 and it extends from the Atacama region to the Magallanes region. “Hantavirus causes a disease that is endemic to Chile, transmitted by the long-tailed pygmy rice rat that lives in rural and semi-rural areas throughout almost the entire country. As a ministry, we are constantly monitoring its behavior and are very concerned and actively working because this year the virus's lethality has increased, and for this reason, we decided to declare this alert. As of last week, there were 46 confirmed cases and 18 deaths, representing a 39% lethality rate,” reported the Undersecretary of Public Health, Dr. Alejandra Pizarro. Cases have occurred in the regions of Valparaíso, Metropolitan, O'Higgins, Maule, Ñuble, Biobío, La Araucanía, Los Ríos, Los Lagos, and Aysén. By comparison, in 2025, there were 44 infections and eight deaths (18% case fatality rate). The health alert, which is preventative and prepared, will allow for the granting of extraordinary powers in the event of serious health emergencies to strengthen surveillance, ensure timely resource management, hire specialized personnel, implement health control measures, and expedite the acquisition of supplies through direct procurement. The alert does not imply that there is an ongoing epidemic or that the healthcare system is overwhelmed. Subscribe to Outbreak News TV on YouTube “Hantavirus is not exclusively a summer virus, as the long-tailed pygmy rice rat is present year-round. Therefore, we urge everyone to take extreme precautions: avoid touching rodents, ventilate homes before entering if they have been closed, clean unused spaces with water and bleach, and keep garbage covered and food stored away. Furthermore, it is crucial to be aware of the symptoms: fever, intense muscle pain, and difficulty breathing. If someone experiences these symptoms and has been in rural or semi-rural areas where the long-tailed pygmy rice rat may have been present, they should immediately go to a health center and inform the medical staff so that a hantavirus diagnosis can be considered promptly,” the official added. Since December 2025, the Pan American Health Organization (PAHO) has maintained an epidemiological alert due to the rise in hantavirus cases throughout the Southern Cone, and that the Ministry of Health had an epidemiological alert in place since November of last year. Chile eliminates leprosy As mentioned above, the Health Alert decree also covers diseases transmitted by the Aedes aegypti, Aedes vexans, and Anopheles pseudopunctipennis mosquitoes, such as dengue and Zika, which, according to the alert, “have a high epidemic potential, which could generate high demand and overload for health facilities.” For these diseases, the alert is in effect from Arica to Los Ríos. The authority stressed that it is essential to prevent mosquitoes from breeding in stagnant water and to monitor any suspected cases of people arriving from abroad infected with any of these diseases, in order to prevent any of these vectors from biting a sick person and starting to spread the disease. In the case of avian influenza, the alert was extended to the entire country, because unlike other years, the disease has been concentrated in wild and farm birds, not in poultry farms, increasing the risk of exposure for people. Outbreak News Today is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Subscribe
FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
A milestone year for Morgridge Summer Science Camp
On July 31, the 20th annual Morgridge Summer Science Camp said good-bye to its final group of campers. Over the course of three one-week sessions, 75 students along with their teachers, from 13 districts across the state, envisioned their futures in the biomedical sciences at the Discovery Building and UW–Madison’s campus.
Biotech is Back: A Wave of Life Science Deals is Pumping Cash into the Sector
Learn more about the latest updates in legal, with expert commentary and insights from trusted attorneys from Foley Hoag LLP. Foley Hoag is a professional community of highly qualified attorneys from all over the US.
Turning fermented food into precision-nutrition for oral and gut health
A new review by researchers at Penn Dental Medicine examines how fermented plant-based foods interact with the microbes that live in the mouth and gut, providing a roadmap for developing fermented foods into nutrition strategies to support health.
AI Cognitive Health Startup Mantis Biotech Rethinks How Women Are Diagnosed
The AI Catching Brain Fog, ADHD, And Dementia Between Doctor Visits
casio turns its ring watch into smart wearable with health tracking and notifications
the CRW-H001 combines digital timekeeping with biometric sensors and smartphone connectivity in a finger-sized device available exclusively in china.